Laninamivir Prodrug CS-8958, a Long-Acting Neuraminidase Inhibitor, Shows Superior Anti-Influenza Virus Activity after a Single Administration▿
Identifieur interne : 000926 ( Pmc/Checkpoint ); précédent : 000925; suivant : 000927Laninamivir Prodrug CS-8958, a Long-Acting Neuraminidase Inhibitor, Shows Superior Anti-Influenza Virus Activity after a Single Administration▿
Auteurs : Shuku Kubo [Japon] ; Takanori Tomozawa [Japon] ; Masayo Kakuta [Japon] ; Akane Tokumitsu [Japon] ; Makoto Yamashita [Japon]Source :
- Antimicrobial Agents and Chemotherapy [ 0066-4804 ] ; 2010.
Abstract
Two neuraminidase (NA) inhibitors, zanamivir (Relenza) and oseltamivir phosphate (Tamiflu), have been licensed for use for the treatment and prophylaxis of influenza. We have reported on laninamivir (code name, R-125489), a novel neuraminidase inhibitor, and have discovered that the laninamivir prodrug CS-8958 worked as a long-acting neuraminidase inhibitor in a mouse influenza virus infection model when it is intranasally administered. In this study, CS-8958 was administered just once 7 days before infection and showed significant efficacy
Url:
DOI: 10.1128/AAC.01311-09
PubMed: 20047917
PubMed Central: 2825999
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:2825999Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Laninamivir Prodrug CS-8958, a Long-Acting Neuraminidase Inhibitor, Shows Superior Anti-Influenza Virus Activity after a Single Administration<xref ref-type="fn" rid="fn2">▿</xref>
</title>
<author><name sortKey="Kubo, Shuku" sort="Kubo, Shuku" uniqKey="Kubo S" first="Shuku" last="Kubo">Shuku Kubo</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tomozawa, Takanori" sort="Tomozawa, Takanori" uniqKey="Tomozawa T" first="Takanori" last="Tomozawa">Takanori Tomozawa</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kakuta, Masayo" sort="Kakuta, Masayo" uniqKey="Kakuta M" first="Masayo" last="Kakuta">Masayo Kakuta</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tokumitsu, Akane" sort="Tokumitsu, Akane" uniqKey="Tokumitsu A" first="Akane" last="Tokumitsu">Akane Tokumitsu</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yamashita, Makoto" sort="Yamashita, Makoto" uniqKey="Yamashita M" first="Makoto" last="Yamashita">Makoto Yamashita</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">20047917</idno>
<idno type="pmc">2825999</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825999</idno>
<idno type="RBID">PMC:2825999</idno>
<idno type="doi">10.1128/AAC.01311-09</idno>
<date when="2010">2010</date>
<idno type="wicri:Area/Pmc/Corpus">000608</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000608</idno>
<idno type="wicri:Area/Pmc/Curation">000608</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000608</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000926</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000926</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Laninamivir Prodrug CS-8958, a Long-Acting Neuraminidase Inhibitor, Shows Superior Anti-Influenza Virus Activity after a Single Administration<xref ref-type="fn" rid="fn2">▿</xref>
</title>
<author><name sortKey="Kubo, Shuku" sort="Kubo, Shuku" uniqKey="Kubo S" first="Shuku" last="Kubo">Shuku Kubo</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tomozawa, Takanori" sort="Tomozawa, Takanori" uniqKey="Tomozawa T" first="Takanori" last="Tomozawa">Takanori Tomozawa</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kakuta, Masayo" sort="Kakuta, Masayo" uniqKey="Kakuta M" first="Masayo" last="Kakuta">Masayo Kakuta</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tokumitsu, Akane" sort="Tokumitsu, Akane" uniqKey="Tokumitsu A" first="Akane" last="Tokumitsu">Akane Tokumitsu</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yamashita, Makoto" sort="Yamashita, Makoto" uniqKey="Yamashita M" first="Makoto" last="Yamashita">Makoto Yamashita</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Antimicrobial Agents and Chemotherapy</title>
<idno type="ISSN">0066-4804</idno>
<idno type="eISSN">1098-6596</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Two neuraminidase (NA) inhibitors, zanamivir (Relenza) and oseltamivir phosphate (Tamiflu), have been licensed for use for the treatment and prophylaxis of influenza. We have reported on laninamivir (code name, R-125489), a novel neuraminidase inhibitor, and have discovered that the laninamivir prodrug CS-8958 worked as a long-acting neuraminidase inhibitor in a mouse influenza virus infection model when it is intranasally administered. In this study, CS-8958 was administered just once 7 days before infection and showed significant efficacy <italic>in vivo</italic>
. The efficacy of a single administration of CS-8958 after viral infection was then compared with that of repeated administrations of oseltamivir phosphate or zanamivir in mice and ferrets. CS-8958 showed efficacy superior or similar to the efficacies of the two licensed NA inhibitors. CS-8958 also significantly reduced the titers of an oseltamivir-resistant H1N1 virus with a neuraminidase H274Y substitution in a mouse infection model. These results suggest that since CS-8958 is characteristically long lasting in the lungs, it may be ideal for the prophylaxis and treatment of influenza.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id>
<journal-id journal-id-type="publisher-id">aac</journal-id>
<journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title>
</journal-title-group>
<issn pub-type="ppub">0066-4804</issn>
<issn pub-type="epub">1098-6596</issn>
<publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">20047917</article-id>
<article-id pub-id-type="pmc">2825999</article-id>
<article-id pub-id-type="publisher-id">1311-09</article-id>
<article-id pub-id-type="doi">10.1128/AAC.01311-09</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Antiviral Agents</subject>
</subj-group>
</article-categories>
<title-group><article-title>Laninamivir Prodrug CS-8958, a Long-Acting Neuraminidase Inhibitor, Shows Superior Anti-Influenza Virus Activity after a Single Administration<xref ref-type="fn" rid="fn2">▿</xref>
</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Kubo</surname>
<given-names>Shuku</given-names>
</name>
<xref ref-type="aff" rid="aff0"></xref>
<xref ref-type="fn" rid="fn1">†</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Tomozawa</surname>
<given-names>Takanori</given-names>
</name>
<xref ref-type="aff" rid="aff0"></xref>
</contrib>
<contrib contrib-type="author"><name><surname>Kakuta</surname>
<given-names>Masayo</given-names>
</name>
<xref ref-type="aff" rid="aff0"></xref>
</contrib>
<contrib contrib-type="author"><name><surname>Tokumitsu</surname>
<given-names>Akane</given-names>
</name>
<xref ref-type="aff" rid="aff0"></xref>
</contrib>
<contrib contrib-type="author"><name><surname>Yamashita</surname>
<given-names>Makoto</given-names>
</name>
<xref ref-type="aff" rid="aff0"></xref>
<xref ref-type="fn" rid="fn1">†</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
</contrib-group>
<aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</aff>
<author-notes><corresp id="cor1"><label>*</label>
Corresponding author. Mailing address: Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan. Phone: 81-3-3492-3131. Fax: 81-3-5436-8578. E-mail: <email>yamashita.makoto.yr@daiichisankyo.co.jp</email>
</corresp>
<fn id="fn1"><label>†</label>
<p>S.K. and M.Y. contributed equally to this study.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub"><month>3</month>
<year>2010</year>
</pub-date>
<pub-date pub-type="epub"><day>4</day>
<month>1</month>
<year>2010</year>
</pub-date>
<volume>54</volume>
<issue>3</issue>
<fpage>1256</fpage>
<lpage>1264</lpage>
<history><date date-type="received"><day>17</day>
<month>9</month>
<year>2009</year>
</date>
<date date-type="rev-recd"><day>26</day>
<month>10</month>
<year>2009</year>
</date>
<date date-type="accepted"><day>18</day>
<month>12</month>
<year>2009</year>
</date>
</history>
<permissions><copyright-statement>Copyright © 2010, American Society for Microbiology</copyright-statement>
<copyright-year>2010</copyright-year>
</permissions>
<self-uri xlink:title="pdf" xlink:href="zac00310001256.pdf"></self-uri>
<abstract><p>Two neuraminidase (NA) inhibitors, zanamivir (Relenza) and oseltamivir phosphate (Tamiflu), have been licensed for use for the treatment and prophylaxis of influenza. We have reported on laninamivir (code name, R-125489), a novel neuraminidase inhibitor, and have discovered that the laninamivir prodrug CS-8958 worked as a long-acting neuraminidase inhibitor in a mouse influenza virus infection model when it is intranasally administered. In this study, CS-8958 was administered just once 7 days before infection and showed significant efficacy <italic>in vivo</italic>
. The efficacy of a single administration of CS-8958 after viral infection was then compared with that of repeated administrations of oseltamivir phosphate or zanamivir in mice and ferrets. CS-8958 showed efficacy superior or similar to the efficacies of the two licensed NA inhibitors. CS-8958 also significantly reduced the titers of an oseltamivir-resistant H1N1 virus with a neuraminidase H274Y substitution in a mouse infection model. These results suggest that since CS-8958 is characteristically long lasting in the lungs, it may be ideal for the prophylaxis and treatment of influenza.</p>
</abstract>
</article-meta>
</front>
</pmc>
<affiliations><list><country><li>Japon</li>
</country>
<region><li>Région de Kantō</li>
</region>
<settlement><li>Tokyo</li>
</settlement>
</list>
<tree><country name="Japon"><region name="Région de Kantō"><name sortKey="Kubo, Shuku" sort="Kubo, Shuku" uniqKey="Kubo S" first="Shuku" last="Kubo">Shuku Kubo</name>
</region>
<name sortKey="Kakuta, Masayo" sort="Kakuta, Masayo" uniqKey="Kakuta M" first="Masayo" last="Kakuta">Masayo Kakuta</name>
<name sortKey="Tokumitsu, Akane" sort="Tokumitsu, Akane" uniqKey="Tokumitsu A" first="Akane" last="Tokumitsu">Akane Tokumitsu</name>
<name sortKey="Tomozawa, Takanori" sort="Tomozawa, Takanori" uniqKey="Tomozawa T" first="Takanori" last="Tomozawa">Takanori Tomozawa</name>
<name sortKey="Yamashita, Makoto" sort="Yamashita, Makoto" uniqKey="Yamashita M" first="Makoto" last="Yamashita">Makoto Yamashita</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000926 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 000926 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= H2N2V1 |flux= Pmc |étape= Checkpoint |type= RBID |clé= PMC:2825999 |texte= Laninamivir Prodrug CS-8958, a Long-Acting Neuraminidase Inhibitor, Shows Superior Anti-Influenza Virus Activity after a Single Administration▿ }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:20047917" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a H2N2V1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |